|1.||Smith, Malcolm A: 4 articles (02/2015 - 07/2010)|
|2.||Harvey, Richard C: 3 articles (02/2015 - 07/2010)|
|3.||Mullighan, Charles G: 3 articles (02/2015 - 07/2010)|
|4.||Willman, Cheryl L: 3 articles (02/2015 - 07/2010)|
|5.||Chen, I-Ming: 3 articles (02/2015 - 07/2010)|
|6.||Hunger, Stephen P: 3 articles (02/2015 - 07/2010)|
|7.||Jove, Richard: 3 articles (11/2014 - 04/2002)|
|8.||Culig, Zoran: 3 articles (01/2014 - 02/2003)|
|9.||Ottani, Alessandra: 2 articles (12/2015 - 12/2014)|
|10.||Rossi, Rosario: 2 articles (12/2015 - 12/2014)|
|1.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/01/2015 - "New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease."
02/20/2015 - "The action of Janus kinases (JAKs) is required for multiple cytokine signaling pathways, and as such, JAK inhibitors hold promise for treatment of autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. "
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/01/2015 - "Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). "
07/01/2010 - "Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia."
04/25/2006 - "Treatment of Arf-/-, p210(Bcr-Abl)-positive pre-B cells with imatinib together with an inhibitor of JAK kinases abrogates this resistance, suggesting that this combination may prove beneficial in the treatment of BCR-ABL-positive acute lymphoblastic leukemia."
06/01/1996 - "Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia."
12/01/2014 - "Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. "
08/01/2014 - "Selective inhibitors of JAK kinases are viewed as of considerable potential as disease-modifying anti-inflammatory drugs for the treatment of rheumatoid arthritis. "
01/01/2014 - "Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib."
08/01/2010 - "Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes."
08/01/2015 - "Because Janus kinases (JAKs) play a crucial role in cytokine-mediated signal transduction, JAKs are an attractive target for the treatment of organ transplant rejection and autoimmune diseases such as rheumatoid arthritis (RA). "
01/01/2014 - "Recently, small molecules, which are inhibitors of Janus kinases (JAKs), hold promise with a tolerable safety profile and efficacy in UC, and the field of nanomedicine is emerging with siRNAs loaded into polyactide nanoparticles that may silence gene transcripts at sites of intestinal inflammation. "
01/22/2014 - "[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)]."
03/01/2010 - "Janus kinases (JAKs) are critical components of cytokine signaling pathways which regulate immunity, inflammation, hematopoiesis, growth, and development. "
02/01/2014 - "Collectively, our results provide the first evidence that pharmacologic targeting of excessively activated wild-type Jak kinases affords therapeutic suppression of inflammation-associated gastrointestinal cancers progression in vivo."
08/27/2015 - "The Janus kinases (JAKs) and their downstream effectors, signal transducer and activator of transcription proteins (STATs), form a critical immune cell signaling circuit, which is of fundamental importance in innate immunity, inflammation, and hematopoiesis, and dysregulation is frequently observed in immune disease and cancer. "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
|1.||Interleukin-12 (IL 12)
|3.||Interleukin-6 (Interleukin 6)
|6.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|7.||Interleukin-7 (Interleukin 7)
|8.||Janus Kinase 3
|9.||Interleukin-7 Receptors (Interleukin 7 Receptor)
|10.||RNA-Directed DNA Polymerase (Reverse Transcriptase)